Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.
LGD-3303
LGD-3303 is an orally active SARM developed by Ligand Pharmaceuticals as a follow-up to LGD-4033. It showed potent anabolic effects on muscle and bone in preclinical studies but has not progressed to human trials.
Risk Level
High RiskDifficulty
Advanced| CAS Number | 917891-35-1 |
| Molecular Formula | C16H14ClF3N2O |
| Class | SARM |
| Category | SARMs |
Mechanism of Action
LGD-3303 is a full agonist at androgen receptors in muscle and bone tissue. It demonstrated greater oral bioavailability and potency than LGD-4033 in animal models. It increased bone mineral density and lean mass while showing tissue selectivity.
Dosing Research
Animal studies used various doses. Research community references 10-20 mg/day. Half-life estimated at 6-12 hours. No established human dosing protocols.
Side Effects & Risks
No human data available. Animal studies suggest significant hormonal suppression. As a full agonist, likely stronger suppression than partial agonists. Unknown long-term safety profile.
Research Studies
Related compounds
Ostarine
SARMOstarine is the most widely studied SARM, originally developed for muscle wasting and osteoporosis. It has completed multiple Phase II and Phase III clinical trials, making it one of the few SARMs with substantial human data.
Ligandrol
SARMLigandrol is a non-steroidal SARM developed by Ligand Pharmaceuticals for muscle wasting conditions. It demonstrated significant lean mass gains in Phase I trials at doses as low as 1 mg/day.
Cardarine
OtherCardarine is not actually a SARM but a PPARδ agonist, often grouped with SARMs commercially. It was developed by GlaxoSmithKline for metabolic and cardiovascular diseases but was abandoned due to cancer findings in rodent studies.
RAD-140
SARMRAD-140 is a potent non-steroidal SARM developed by Radius Health. It has shown neuroprotective properties in preclinical studies and is currently in early clinical trials for breast cancer.
Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.